

SUBJECT INDEX TO VOLUME 1

<p>Accentia biopharmaceuticals-sponsored clinical trial (BIOVAXID) 69</p> <p>Actinic keratoses 53</p> <p style="padding-left: 20px;">colchicine in 57</p> <p style="padding-left: 20px;">diclofenac in 56</p> <p style="padding-left: 20px;">5-flourouracil in 53</p> <p style="padding-left: 20px;">imiquimod in 55</p> <p style="padding-left: 20px;">retinoids in 57</p> <p style="padding-left: 20px;">topical therapy for 53</p> <p>Acute myeloid leukaemia (AML) 103</p> <p style="padding-left: 20px;">antibody treatment for 108</p> <p style="padding-left: 20px;">colony stimulating factors for 106</p> <p style="padding-left: 20px;">disease resistance in 107</p> <p style="padding-left: 20px;">GM-CSF for 106</p> <p style="padding-left: 20px;">high dose ara-C with mitoxantrone for 105</p> <p style="padding-left: 20px;">high dose cytarabine for 103</p> <p style="padding-left: 20px;">timed sequential chemotherapy for 106</p> <p style="padding-left: 20px;">treatment of relapse of 103</p> <p>Alefacept 163</p> <p style="padding-left: 20px;">for plaque psoriasis 163</p> <p>Anastrozole 211</p> <p style="padding-left: 20px;">safety profile of 211</p> <p>Antiemetics 61</p> <p>Antitumor activity 171</p> <p style="padding-left: 20px;">early- to late-phase trials of 171</p> <p>Arimidex 207</p> <p style="padding-left: 20px;">in treatment of early breast cancer 207</p> <p>Aromatase inhibitors 237</p> <p style="padding-left: 20px;">ABCSG 6a trial of 245</p> <p style="padding-left: 20px;">ARNO/ABCSG8 trial of 244</p> <p style="padding-left: 20px;">BIG 1-98 trial of 243</p> <p style="padding-left: 20px;">efficacy in adjuvant treatment of 240</p> <p style="padding-left: 20px;">IES trial of 244</p> <p style="padding-left: 20px;">in adjuvant management of breast cancer 237</p> <p style="padding-left: 20px;">in first line metastatic disease 238</p> <p style="padding-left: 20px;">ITA trial of 244</p> <p style="padding-left: 20px;">lipid metabolism/cardiac toxicity of 247</p> <p style="padding-left: 20px;">MA17 trial of 245</p> <p style="padding-left: 20px;">mechanism of action of 238</p> <p style="padding-left: 20px;">musculoskeletal toxicities of 247</p> <p style="padding-left: 20px;">pharmacology of 238</p> <p style="padding-left: 20px;">toxicity profile of 247</p> <p>ATAC 207</p> <p style="padding-left: 20px;">treatment analysis on 209</p> <p>Atorvastatin 143</p> <p style="padding-left: 20px;">and angioplasty 144</p> <p style="padding-left: 20px;">clinical trials of 143</p> <p style="padding-left: 20px;">collaborative atorvastatin diabetes study (CARDS) for 145</p> <p style="padding-left: 20px;">effect on cardiovascular endpoints 143</p> <p style="padding-left: 20px;">effect on vessel structure/function 146</p> <p style="padding-left: 20px;">in calcific aortic stenosis 145</p> <p style="padding-left: 20px;">kidney disease in 146</p> <p style="padding-left: 20px;">trials comparing does of 146</p> <p style="padding-left: 20px;">trials comparing placebo with 144</p>	<p>vascular function of 145</p> <p>vs. fluvastatin/rosuvastatin 149</p> <p>vs. lovastatin 148</p> <p>vs. pravastatin 147</p> <p>vs. pravastatin/simvastatin/lovastatin/fluvastatin ... 149</p> <p>vs. simvastatin 148</p> <p>with amlodipine 150</p> <p>with ASCOT-LLA trial 145</p> <p>with ezetimibe 150</p> <p>with GREACE trial 144</p> <p>with MIRACL trial 144</p> <p>with/without fibrates 149</p> <p>5-Aza-2'-deoxycytidine (decitabine) 172</p> <p style="padding-left: 20px;">early clinical trials of 172</p> <p style="padding-left: 20px;">early- to late-phase trials of 172</p> <p>5-Azacytidine 171</p> <p style="padding-left: 20px;">clinical trials for 172,173</p> <p style="padding-left: 20px;">early-phase trials of 171</p> <p>Cancer 175,283</p> <p style="padding-left: 20px;">allogeneic tumor cell lysate for 286</p> <p style="padding-left: 20px;">allogeneic vaccines for 286</p> <p style="padding-left: 20px;">allogeneic whole tumor cells for 286</p> <p style="padding-left: 20px;">autologous tumor vaccines for 286</p> <p style="padding-left: 20px;">autologous vaccines for 286</p> <p style="padding-left: 20px;">carbohydrate vaccines for 284</p> <p style="padding-left: 20px;">cytokine modified tumor vaccines for 287</p> <p style="padding-left: 20px;">dendritic cell vaccines for 287</p> <p style="padding-left: 20px;">DNA/RNA vaccines for 285</p> <p style="padding-left: 20px;">HDAC/histone acetyl transferase activities in 175</p> <p style="padding-left: 20px;">heat shock proteins for 286</p> <p style="padding-left: 20px;">peptide vaccines for 284</p> <p style="padding-left: 20px;">protein vaccines for 284</p> <p style="padding-left: 20px;">specific active immunotherapy of 283</p> <p style="padding-left: 20px;">target antigens for 284</p> <p style="padding-left: 20px;">types of vaccines for 284</p> <p style="padding-left: 20px;">viral vectors for 285</p> <p>Carotid endarterectomy (CEA) 293</p> <p style="padding-left: 20px;">for asymptomatic carotid disease 294</p> <p style="padding-left: 20px;">indications for 293</p> <p style="padding-left: 20px;">timing of 295</p> <p>Chemotherapy induced emesis 61</p> <p style="padding-left: 20px;">antiemetic trials for 61</p> <p style="padding-left: 20px;">aprepitant trials for 61</p> <p>Cladribine 15</p> <p style="padding-left: 20px;">autoimmune disorders in 15</p> <p style="padding-left: 20px;">clinical trials of 15</p> <p style="padding-left: 20px;">in acute myeloid leukemia 25</p> <p style="padding-left: 20px;">in autoimmune diseases 29</p> <p style="padding-left: 20px;">in chronic lymphocytic leukemia 17</p> <p style="padding-left: 20px;">in hairy cell leukemia 16</p> <p style="padding-left: 20px;">in hematological malignancies 15</p> <p style="padding-left: 20px;">in indolent lymphoid malignancies 23</p> <p style="padding-left: 20px;">in multiple sclerosis 27</p> <p style="padding-left: 20px;">in Waldenstrom's macroglobulinemia 23</p>
---	--

Clinical trials	251	in treatment of psoriasis/psoriatic arthritis	259
in children	251	safety of	262
Colorectal cancer (CRC)	113	Extracranial carotid artery disease	293
alternative pathways of EGFR-inhibitor		contrast arteriography in	295
(EGFR-i) resistance in	116	duplex ultrasonography in	295
cetuximab for	114	magnetic resonance angiography in	295
clinical studies with EGFR inhibitors for	113	management of	293
epidermal growth factor receptor in	113	surgical procedure for	296
markers of sensitivity in	113		
mechanisms of EGFR-inhibitor resistance in	114	Favrille-sponsored clinical trial (FavId)	70
monoclonal antibodies against	113	Follicular lymphoma	68
panitumumab for	113	phase III clinical trials of	68
Cytidine analogues	170		
mechanisms of action of	170	Gastrointestinal stromal tumors	35
		AMG 706 in	39
Dendritic cells (DC)	87	ecteinascidin 743 in	40
biology of	87	in imatinib mesylate	36
considerations for clinical-grade of	94	medical treatment of	35
cytokines for	94	mTOR/protein kinase C (PKC) inhibitors in	39
directions of immunotherapy by	97	PTK 787/ZK787 in	39
maturation of	95	SU 11248 in	38
Dendritic cells vaccine	89	Gene therapy	155
antigen delivery strategy of	94	<i>ex vivo</i> phase I/II of	160
clinical trial design of	96	for dystrophic epidermolysis bullosa	159
dosage/boosters of	96	for epidermolysis bullosa	155
in immunotherapy	94	for epidermolysis bullosa simplex	159
route of vaccine administration of	95	for junctional epidermolysis bullosa	159
DNA methylation	169	keratinocyte stem cell	155
as target	169	targeting in	155
DNMT1 antisense	174	Genitope corporation-sponsored clinical trial (MyVax)	70
		Glioblastoma	265
Efalizumab	165	adoptive cellular therapy for	275
clinical response of	166	antibodies for	273
dosing of	168	CCI-779 for	271
for treatment of psoriasis	165	chemotherapy for	266
pharmacodynamics of	166	clinical trials for	265
pharmacokinetics of	166	epidermal growth factor receptor (EGFR)-based	
safety of	167	therapies for	269
Epidermal growth factor receptor (EGFR)	1,113	erlotinib HCl for	269
biology of	113	farnesyltransferase inhibitors (FTI) for	272
gene copy number of	6	gefitinib for	270
gene mutations of	4	gliadel for	266
ligand expression in	116	imatinib for	270
mutations in	115	immunotherapy for	273
physiology of	113	immunotoxins for	274
polymorphisms in	115	inhibitors of molecular targets for	269
targeted therapies in non-small cell lung cancer		mammalian targets of rapamycin (mTOR)	
(NSCLC)	1	inhibitors for	271
Epidermolysis bullosa	155	matrix metalloproteinase (MMP) inhibitors for	272
gene therapy clinical trial for	155	temozolomide for	267
Epigenetic therapy	169	tumor vaccines for	275
clinical trials in	169	Glioblastoma multiforme	43
Etanercept	259	combined modality treatment of	43
in psoriasis	260	postoperative chemotherapy for	44
in psoriatic arthritis	261	postoperative radiotherapy for	44
		prognostic factors for	44

Soluble protein idiotype vaccines	68	Thyroid carcinoma	133
Stem cell transduction	157	anaplastic transformation of	135
<i>ex vivo</i> gene delivery strategies for	157	biology of	134
non-integrating viral vectors for	157	chemotherapy for	136
nonviral vectors for	157	iodine-refractory type	133
retro-/lentivirues for	157	re-differentiation therapy for	136
Stroke	75	role of B-RAF in	134
developments in rehabilitation research for	75	role of Ras in	134
efficacy of rehabilitation in	76	role of RET in	134
functional recovery after	75	role of TP53 tumor suppressor gene in	134
measurement/prediction in	77	targeted therapy for	138
Symptomatic carotid artery disease	293	therapeutic options for	136
Tamoxifen	207	Tocilizumab	193
in treatment of early breast cancer	207	adverse events of	197
Targeted toxins	120	clinical trials with	195
clinical development of	123	effect on systemic lupus erythematosus	197
delivery mode of	123	effects on animal models	194
IL13-PE38 as	125,127	efficacy on Castleman's disease	197
NBI-3001 (IL4-PE) as	123	efficacy on Crohn's disease	197
NBI-3001 (IL4-PE) as	127,128	efficacy on rheumatoid arthritis	195
pharmacokinetics in CNS	123	metabolism/toxicity of	194
phase I/combined phase I/II studies of	123	pre-clinical development of	193
phase II studies of	127	Tyrosine kinase inhibitor	3
phase III studies of	128	biological markers predicting sensitivity to	4
preclinical investigations of	120	clinical markers predicting sensitivity to	3
properties of	120	University clinic of Navarre (CUN)-sponsored clinical trial (FLIDVAX)	72
TP-38 as	127,128	Vorinostat	175
transMID-107 (Tf-CRM107) as	127,128		
Temozolomide	43		
for GBM	45		